ATR

ATR

ATR is a large serine/threonine protein kinase central to the cellular response to DNA replication stress and single-stranded DNA. Discovered through biochemical and genetic screens in model organisms, ATR coordinates checkpoints that preserve genome integrity during S phase and after genotoxic insults. ATR functions in concert with numerous factors to detect DNA structures, activate signal transduction cascades, and regulate cell cycle progression, DNA repair, and apoptosis.

Overview

ATR was first identified through comparisons with ATM kinase family members and characterized by sequence homology to PI3K-related kinases such as DNA-PKcs and mTOR. Orthologs and functional counterparts exist in Saccharomyces cerevisiae (Mec1), Schizosaccharomyces pombe (Rad3), and metazoans studied in laboratories using Xenopus laevis egg extracts and Drosophila melanogaster genetics. ATR operates as part of a conserved checkpoint pathway that includes the obligate partner ATRIP and downstream effector kinases like CHK1. ATR signaling is activated by genotoxic events that produce prolonged stretches of single-stranded DNA coated with Replication protein A, and by stalled replication forks during challenges such as treatment with hydroxyurea or exposure to ultraviolet light from UV radiation.

Structure and Mechanism

ATR is a member of the phosphatidylinositol 3-kinase-related kinase superfamily, sharing the C-terminal kinase domain architecture seen in ATM kinase and TRRAP. ATR associates constitutively with ATRIP, analogous to the ATR–ATRIP module defined in studies using recombinant proteins and structural analysis informed by cryo-electron microscopy and crosslinking mass spectrometry. ATR contains HEAT repeat regions that mediate protein–protein interactions with sensors and adaptors including TOPBP1, the 9-1-1 complex composed of RAD9, RAD1, and HUS1, and the single-stranded DNA-binding heterotrimer RPA. Activation of ATR requires recruitment to RPA-coated single-stranded DNA via ATRIP and stimulatory interaction with the ATR-activating domain of TOPBP1 or alternative activators such as ETAA1. Once localized, ATR phosphorylates substrates on SQ/TQ motifs, notably activating CHK1 through phosphorylation at serine residues that were mapped in phosphoproteomic screens.

Biological Functions and Pathways

ATR’s principal role is to preserve replication fork stability and enforce S-phase checkpoints, preventing premature entry into mitosis when DNA is incompletely replicated. ATR-mediated phosphorylation events regulate factors involved in origin firing, including CDC25A and components of the pre-replication complex such as MCM2-7 helicase subunits characterized in biochemical assays. In addition to cell-cycle control, ATR influences DNA repair pathway choice by modulating nucleases like MUS81 and scaffold proteins such as BRCA1 and BRCA2, which feature in homologous recombination pathways elucidated in studies with HeLa cells and patient-derived cell lines. ATR also impacts telomere maintenance through interactions with shelterin components studied in mouse models and human cell systems, linking ATR activity to responses at stalled forks occurring at fragile sites like common fragile sites identified cytogenetically.

Clinical Significance and Diseases

Germline hypomorphic mutations in ATR produce developmental syndromes exemplified by Seckel syndrome, characterized by microcephaly and growth retardation identified through clinical genetics and exome sequencing consortia. Somatic alterations and dysregulation of ATR signaling are implicated in tumorigenesis across cancers profiled by The Cancer Genome Atlas and studied in xenograft models, where ATR dependency creates therapeutic vulnerabilities in tumors with defects in ATM kinase or BRCA1/BRCA2. Small-molecule ATR inhibitors have advanced into clinical trials overseen by regulatory agencies and cooperative groups, often tested in combination with DNA-damaging chemotherapies like cisplatin or targeted agents such as PARP inhibitors to exploit synthetic lethality. Conversely, ATR activation has been explored as a protective strategy against replication-stress–induced degeneration in certain neurodevelopmental disorders modeled in zebrafish and mouse systems.

Research Tools and Experimental Studies

Key experimental approaches for ATR research include genetic knockouts and conditional alleles in Mus musculus, siRNA and CRISPR screens in human cancer cell lines such as U2OS and HCT116, and biochemical reconstitution using purified ATR–ATRIP complexes analyzed by kinase assays. Small-molecule inhibitors (e.g., selective ATR kinase inhibitors disclosed in medicinal chemistry literature) and allosteric activators are used to perturb signaling in vitro and in vivo, while phospho-specific antibodies against CHK1 and other ATR substrates enable pathway readouts in immunoblotting and immunofluorescence studies. Single-molecule and electron microscopy approaches have probed ATR recruitment at model replication forks formed on plasmids or in Xenopus egg extract systems, while high-throughput screens combining drug libraries and genomic profiling in panels like the Cancer Cell Line Encyclopedia map ATR dependency across tumor types. Clinical translational studies monitor pharmacodynamic biomarkers, including phosphorylation of CHK1 and markers of replication stress such as RPA phosphorylation, in trials coordinated by academic consortia and pharmaceutical partners.

Category:Protein kinases